Pharma major Biocon has received European Commission approval for Pebrilzo®, its biosimilar version of pertuzumab, for the treatment of HER2-positive breast cancer across multiple stages of the disease in the European Union (EU).
Shreehas Tambe, Chief Executive Officer and Managing Director of Biocon, said: “The European Commission’s approval of Pebrilzo®, our pertuzumab biosimilar, the first under its new tailored clinical pathway, marks a significant regulatory milestone for Biocon. With this approval, pertuzumab becomes our fifth oncology biosimilar approved in both Europe and the US, strengthening our global oncology portfolio.”
Biocon’s pertuzumab biosimilar is indicated for use in combination with trastuzumab and chemotherapy in the neoadjuvant treatment of adults with HER2-positive, locally advanced, inflammatory or early-stage breast cancer at high risk of recurrence. It is also indicated for the adjuvant treatment of adults with HER2-positive early breast cancer at high risk of recurrence.
The company’s oncology portfolio spans multiple areas of cancer care, including solid tumours such as breast cancer and supportive care for chemotherapy-induced neutropenia.
Published on November 18, 2026




